List view / Grid view
New findings from collaborative research in the United States have identified a promising new treatment avenue for type 2 diabetes patients centring on the activity of the amino acid, GABA.
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.
Researchers have shown a gene therapy to correct the genetic mutation that causes Danon disease is successful in pre-clinical trials.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
